Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression

作者：Emily Y. Chew, Traci E. Clemons, Elvira Agrón, Amitha Domalpally, Tiarnán D L Keenan, Susan Vitale, Claire Weber, Douglas C. Smith, William G. Christen, John Paul SanGiovanni, Federick L Ferris, Ronald P. Danis, Barbara A. Blodi, Alan J. Ruby, Andrew N. Antoszyk, Ronald Klein, Ivana K. Kim, Gary E. Fish, Wai T. Wong, David H. Orth, Kourous A. Rezaei, Susan B. Bressler, GB Hubbard, Michael J. Elman, Suresh Chandra, Thomas R. Friberg, Michael Tolentino, Darmakusuma Le, Mary B. Lansing, Jay B. Stallman, Paul Andrew Edwards, Carl W. Baker, Michael A Novak, Ricky D. Isernhagen, Todd E. Schneiderman, Lawrence S. Halperin, Michael Ho-Yan Lee, David S. Boyer, Philip J. Rosenfeld, Pamela P. Rath, Marc H. Levy, Robert H. Rosa, John C. Hoskins, Clement K. Chan, David M. Brown, Craig M. Greven, J Michael Jumper, Linda J. Margulies, William N. Rosenthal, Richard B. Rosen, Glenn Stoller, Fadi El Baba, W. Copley McLean, Ronald M. Kingsley, Alice T. Lyon, Jeffrey S. Heier, Anne E. Fung, Ingrid Ursula Scott, John A. Wells, Michael J. Banach, Paul M. Beer, James C. Folk, Joseph I. Maguire, Srinivas Reddy Sadda, Richard A. Garfinkel, Judy E. Kim, Paul Berstein, Michael Rauser, Richard Alan Lewis, Barron C. Fishburne, Suber Huang, Nelson R. Sabates, Nicola Kim, Robert N. Frank, Brian C. Joondeph, Odette Margit Houghton, Dean P. Hainsworth, Edward Chaum, Robert H. Millay, Raymond Iezzi, Rajendra S. Apte, Ron Afshari Adelman, Anita Agrawal, Neelakshi Bhagat, Lawrence Ulanski, Steven D. Schwartz, Cynthia J. Owsley, Alan Letson, Yu-Guang He, Cynthia Ann Toth, Lawrence S. Morse, Michael J. Cooney, Sandeep Grover, Henry A. Ferreyra, Alexander J. Brucker, David Allen DiLoreto, Aaron B. Weinberg · 发表于：JAMA Ophthalmology · 年份：2022 · DOI：10.1001/jamaophthalmol.2022.1640 · 被引用次数：186 · 研究领域：Retinal Diseases and Treatments、Antioxidant Activity and Oxidative Stress、Ophthalmology and Visual Impairment Studies

Importance: After the Age-Related Eye Disease Study 2 (AREDS2) study, the beta carotene component was replaced by lutein/zeaxanthin for the development of the revised AREDS supplement. However, it is unknown if the increased risk of lung cancer observed in those assigned beta carotene persists beyond the conclusion of the AREDS2 trial and if there is a benefit of adding lutein/zeaxanthin to the original AREDS supplement that can be observed with long-term follow-up. Objective: To assess 10-year risk of developing lung cancer and late age-related macular degeneration (AMD). Design, Setting, and Participants: This was a multicenter epidemiologic follow-up study of the AREDS2 clinical trial, conducted from December 1, 2012, to December 31, 2018. Included in the analysis were participants with bilateral or unilateral intermediate AMD for an additional 5 years after clinical trial. Eyes/participants were censored at the time of late AMD development, death, or loss to follow-up. Data were analyzed from November 2019 to March 2022. Interventions: During the clinical trial, participants were randomly assigned primarily to lutein/zeaxanthin and/or ω-3 fatty acids or placebo and secondarily to no beta carotene vs beta carotene and low vs high doses of zinc. In the epidemiologic follow-up study, all participants received AREDS2 supplements with lutein/zeaxanthin, vitamins C and E, and zinc plus copper. Outcomes were assessed at 6-month telephone calls. Analyses of AMD progression and lu...